NSE: ERIS | BSE: 540596

Falling Comet

Download real time

1184.70 -3.90 (-0.33%)

New 52W Low in past week

50,144 NSE+BSE Volume

NSE 06 Oct, 2026 3:31 PM (IST)

16,436.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

Eris Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ERIS, BSE:540596 Eris Lifesciences Ltd.

Search Inside the pdf :

Eris Lifesciences Ltd.

29 Jul 2026

1184.70

-0.33%

Domestic branded formulation drives earnings Remediation measures weigh on the international business

Neutral: Eris Lifesciences Ltd.

Target

Motilal Oswal

Eris Lifescience (ERIS) delivered slightly better-than-expected revenue for the quarter. However, EBITDA/PAT were marginally below our estimates (4%/6% miss).

Eris Lifesciences Ltd. has an average target of 1663.67 from 3 brokers.

Eris Lifesciences Ltd.

16 Feb 2026

1184.70

-0.33%

Eris Lifesciences (ERIS IN) Q3FY26 Result Update Growth to improve BUY

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

up 12.5% YoY). Though 9MFY26 revenue growth (up 8% YoY) was muted, we from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 36% in FY26...

Eris Lifesciences Ltd. is trading below all available SMAs

Eris Lifesciences Ltd.

15 Feb 2026

1184.70

-0.33%

Eris Lifesciences (BUY): Domestic and Internation growth levers remain intact

Buy: Eris Lifesciences Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 2%/-1.5%/2.3% above our estimates. EBITDA Margin reported 110 bps below our estimates

Promoters unpledged 0.07% of shares in last quarter. Total pledge stands at 16.85% of promoter holdings

Eris Lifesciences Ltd.

14 Feb 2026

1184.70

-0.33%

Segment-specific measures lead to a miss on earnings

Neutral: Eris Lifesciences Ltd.

Target

Motilal Oswal

Eris Lifesciences (ERIS) reported lower-than-expected performance with a 4%/8%/11% miss on revenue/EBITDA/PAT for the quarter. ERIS witnessed strong growth in the international business.

Eris Lifesciences has lost -25.64% in the last 1 Year

Eris Lifesciences Ltd.

22 Dec 2025

1184.70

-0.33%

Eris Lifesciences (HOLD): Long tail to GLP opportunity

Hold: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

We hosted IR Head Kruti Raval & team member Atul Modi. Eris is excited to participate in GLP wave. Launch price to be Rs 3.5-4k/month

Promoters unpledged 0.07% of shares in last quarter. Total pledge stands at 16.85% of promoter holdings

Eris Lifesciences Ltd.

14 Nov 2025

1184.70

-0.33%

Eris Lifesciences (HOLD): All positives priced in

Hold: Eris Lifesciences Ltd.

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 1%/3%/0.1% above our estimates. EBITDA margin reported 80 bps above our estimates at 36.4%

Eris Lifesciences has lost -25.64% in the last 1 Year

Eris Lifesciences Ltd.

12 Nov 2025

1184.70

-0.33%

Steady execution in DF drives earnings

Neutral: Eris Lifesciences Ltd.

Target

Motilal Oswal

Eris Lifesciences (ERIS) reported in-line revenue/EBITDA for the quarter. However, there was a slight miss on earnings due to higher interest costs and tax rate for the quarter.

Promoters unpledged 0.07% of shares in last quarter. Total pledge stands at 16.85% of promoter holdings

Eris Lifesciences Ltd.

08 Aug 2025

1184.70

-0.33%

Eris Lifesciences (HOLD): All positives priced in; downgrade to HOLD

Hold: Eris Lifesciences Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Domestic business margin increased by 37.5% and Biocon's margin by 1100 bps to 30%. Consol EBITDA margin at 35.8%

Eris Lifesciences has lost -25.64% in the last 1 Year

Eris Lifesciences Ltd.

06 Aug 2025, 12:00AM

1184.70

-0.33%

Eris Lifesciences (ERIS IN) Q1FY26 Result Update Revenue...

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

Eris Lifesciences' (ERIS) Q1FY26 EBITDA was broadly in line with our estimate (Rs2.75bn; up 11% YoY). Though Q1FY26 revenue growth (up 7.4% YoY) was muted, we see pick up in coming quarters as insulin shortages stabilize, export pick up and likely additional market share gain from human insulin market. Eris has opted for inorganic route to diversify and scale up existing portfolio. This has been implemented without diluting margins. We expect margins to scale up from the current level of 35% in FY25 as revenue scales up from recent...

Eris Lifesciences Ltd. has an average target of 1663.67 from 3 brokers.

Eris Lifesciences Ltd.

20 May 2025

1184.70

-0.33%

Eris Lifesciences (ERIS IN) Q4FY25 Result Update Multiple...

Buy: Eris Lifesciences Ltd.

Target

Prabhudas Lilladhar

Strong FY26 guidance with +15% revenue growth with 36% OPM. up 70% YoY). Eris has opted for inorganic route to diversify and scale up expect margins to scale up from the current level of 35% as revenue scales up from recent acquisitions, which are currently operating at sub-optimal profitability. The company has multiple growth levers such as broad-based...